Market Cap 79.846B USD Sector(s): Healthcare Industry: Medical Devices Full-Time Employees: 14,900 (2020) Edwards Lifesciences total assets for the quarter ending September 30, 2021, were $8.160B, a 19.99% increase year-over-year.
Edwards Lifesciences Corporation makes and sells products and technologies for structural heart disease, critical care, and surgical monitoring in the United States, Europe, Japan, and other places around the world. It sells heart valve replacement products that don't require a lot of surgery. It also sells heart valve repair and replacement products to treat mitral and tricuspid valve problems. Additionally, the company offers surgical heart valve therapy products, including pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; and a beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors.
Edwards Lifesciences Corp (EW.xnys) News; Critical Care - Edwards plans to drive growth and leadership with innovations in critical care technologies, with the goal of improving care for 20 million patients annually. The company is currently integrating a full range of Smart Recovery technologies on the HemoSphere monitoring platform that will create a unique offering of enhanced recovery tools to further strengthen the company’s leadership in smart monitoring. Furthermore, in 2022, Edwards anticipates the U.S. launch of its Viewfinder network connectivity solution and the initiation of the SMART BP study. Edwards believes the global hemodynamic monitoring market opportunity will reach approximately $2 billion by 2028.
December 20, 2021 IRVINE, Calif., Dec. 20, 2021 /PRNew swire Edwards Lifesciences (NYSE: EW) today announced it received approval from the U.S. Food and Drug Administration (FDA) for the use of the Edwards SAPIEN 3 transcatheter valve with the Alterra adaptive present (SAPIEN 3 with Alterra) for patients with severe pulmonary regurgitation.
Edwards Lifesciences Corp (EW)
Explore Edwards Lifesciences Corp (EW) share price and insights to make informed trading decisions. Stay updated with FP Markets Paraguay.